Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked epileptic seizures resulting from abnormal, excessive, and synchronized electrical activity in a group of brain neurons. According to the WHO, it affects approximately 50 million people worldwide. Seizures manifest in a wide variety of ways depending on the brain regions involved: generalized tonic-clonic seizures, absence seizures, and focal seizures with or without impaired consciousness. Diagnosis is based on an electroencephalogram (EEG), brain MRI, and clinical neurological evaluation. Treatment is medical, prescribed and monitored by a specialist neurologist—no over-the-counter product treats epilepsy or serves as a substitute for antiepileptic drugs.
Several factors have been identified as potential triggers for seizures in people with epilepsy:
Magnesium is a physiological modulator of neuronal excitability: it physiologically blocks NMDA receptors for glutamate, the primary excitatory neurotransmitter. Magnesium deficiency is associated with neuronal hyperexcitability and has been documented in some people with epilepsy. Preliminary data suggest that correcting a documented deficiency may help reduce seizure frequency, in addition to medical treatment. Any magnesium supplementation in a person with epilepsy should be discussed with the treating neurologist, as certain antiepileptic drugs may interact with magnesium and calcium levels. This is by no means a treatment for epilepsy.
Preliminary research is examining the role of EPA/DHA omega-3s in modulating neuronal membrane excitability. Polyunsaturated fatty acids influence the fluidity of neuronal membranes and may modulate the ion channels involved in epileptogenesis. Pilot studies have shown modest results regarding seizure frequency, but the evidence remains insufficient to make recommendations. Vitamin D3 warrants attention in this context: a high prevalence of vitamin D deficiency has been documented in people with epilepsy, particularly due to hepatic enzyme induction by certain antiepileptic drugs (phenytoin, carbamazepine, valproate), which accelerate the catabolism of vitamin D. Vitamin D3 supplementation, following a blood test, is often medically recommended in this context. These approaches are exclusively part of a medically validated nutritional supplementation regimen.
Coenzyme Q10 is being studied in mitochondrial epilepsy, a subgroup of epileptic disorders linked to mitochondrial dysfunction. In these specific forms, supplementation may be medically prescribed. Outside of these mitochondrial forms, its benefit remains unestablished. Melatonin is being studied for its potential neuroprotective properties, but clinical data remain preliminary. Its primary use in the context of epilepsy is to improve sleep quality, a major trigger for seizures. Any use of melatonin by a person with epilepsy must be approved by their treating physician.
Daily management of epilepsy relies on several essential practical precautions:
